Micafungin Pharmazac 100 Mg

Micafungin, the active ingredient in Micafungin Pharmazac 100 Mg, is an echinocandin presented as a 100 mg injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is used for prophylaxis of Candida infections in hematopoietic stem cell transplant recipients and for Candida peritonitis and intra‑abdominal infections.

GNH USA supplies Micafungin Pharmazac 100 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal indicated for several serious Candida infections. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: eradicates Candida infection of the esophagus in immunocompromised patients. - Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infections during the high‑risk transplant period. - Candida peritonitis and intra‑abdominal infections: used as part of therapy for intra‑abdominal Candida infections.

Micafungin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Elevated liver enzymes: transient increases in ALT or AST. - Fever: mild to moderate temperature rise. - Nausea: occasional stomach upset. - Phlebitis at infusion site: irritation or redness where the IV is placed.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Severe hypersensitivity reactions: rash, pruritus, or anaphylaxis. - Neutropenia: marked reduction in neutrophil count. - Renal impairment: acute kidney injury in susceptible patients.

When using Micafungin, clinicians should observe several precautions to minimize risks and ensure optimal therapy. - Liver function monitoring: assess ALT, AST, bilirubin before and during treatment. - Renal function assessment: evaluate creatinine clearance in patients with kidney disease. - Drug interactions: review concomitant medications that affect hepatic metabolism. - Pregnancy and lactation: consider risk‑benefit; use only if clearly needed. - Pediatric use: dosage adjustment may be required; follow specialist guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may raise toxicity risk. - Rifampin: strong enzyme induction can markedly reduce micafungin plasma levels. - Antifungal azoles (e.g., fluconazole): may increase micafungin concentrations leading to hepatotoxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Statins (e.g., simvastatin): possible increased risk of myopathy; observe muscle symptoms. - Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible changes.